Solid recs.

A recent ASCO post calls for bone-modifying agents (BMA) for all breast cancer patients with bone mets. This can, and should, be used in conjunction with other supportive care interventions. As a reminder, Zometa can now be given as infrequently as every 12 weeks. No BMA has been proven superior to any other, so start off with one that best supports both your patient’s bones and pocketbook.